Faron Announces First HMA-failed MDS Patient Dosed with Bexmarilimab as part of Phase 2 of BEXMAB Trial
Faron Pharmaceuticals Ltd. (“Faron” or the “Company”) Inside information: Faron Announces First HMA-failed MDS Patient Dosed with Bexmarilimab as part of Phase 2 of BEXMAB Trial - Phase 2 of the trial aims to recruit 32 patients with HMA-failed MDS and to provide final and optimized dosing for registrational study - Company is exploring further development opportunities within the bexmarilimab program in hematological cancer patients following positive feedback from the recent ASH congress Company Announcement, Inside